US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Aktis Oncology, Inc. (AKTS): Radiopharmaceutical Bio IPO Delivers Breakout to Open 2026 Calendar

Aktis Oncology, Inc. (AKTS): Radiopharmaceutical Sets Terms for IPO Seeking $840m Valuation

Aktis Oncology, Inc. (AKTS): Peeking at the IPO Prospectus of a Radiopharmaceutical Company

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Aktis Oncology is the first 2026 IPO, pricing 11.8 million shares at $16–$18, supported by blue-chip biotech investors and an oversubscribed order book.</li>
<li>The company is advancing next-generation alpha-emitting radiopharmaceuticals, led by a Phase 1b Nectin-4 program and a second IND planned for 2026.</li>
<li>A major Eli Lilly collaboration and strong institutional backing reinforce credibility, execution confidence, and an attractive near-term risk-reward profile.</li>
</ul>


Aktis Oncology is the first 2026 IPO, pricing 11.8 million shares at $16–$18, supported by blue-chip biotech investors and an oversubscribed order book.
The company is advancing next-generation alpha-emitting radiopharmaceuticals, led by a Phase 1b Nectin-4 program and a second IND planned for 2026.
A major Eli Lilly collaboration and strong institutional backing reinforce credibility, execution confidence, and an attractive near-term risk-reward profile.


Aktis Oncology, Inc. (AKTS): Lilly Collaboration, Notable Backers Make for Intriguing IPO